Research Analysts Set Expectations for TRVI FY2030 Earnings

Key Points

• HC Wainwright cut its FY2030 EPS forecast for Trevi to $0.70 from $0.79 while maintaining a Buy rating and a $21.00 price target; the current consensus full-year estimate is a loss of ($0.46) per share.
• Overall analyst sentiment is positive with a consensus rating of Buy and a consensus target price of $21.70 (2 Strong Buy, 9 Buy, 1 Sell).
• Shares opened at $14.26 with a $1.83 billion market cap and a negative PE (-44.56); the stock recently reported an EPS miss of ($0.09) vs. ($0.07) and trades in a 52-week range of $5.38–$16.12.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at HC Wainwright decreased their FY2030 earnings estimates for Trevi Therapeutics in a research report issued to clients and investors on Wednesday, May 6th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.70 per share for the year, down from their prior forecast of $0.79. HC Wainwright currently has a "Buy" rating and a $21.00 target price on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.46) per share.

Other equities analysts also recently issued reports about the company. Morgan Stanley restated an "overweight" rating and issued a $20.00 price target on shares of Trevi Therapeutics in a research note on Wednesday. Weiss Ratings restated a "sell (d-)" rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Needham & Company LLC dropped their price target on Trevi Therapeutics from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Wednesday. JonesTrading dropped their price target on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research note on Thursday, March 19th. Finally, D. Boral Capital restated a "buy" rating and issued a $19.00 price target on shares of Trevi Therapeutics in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $21.70.

Trevi Therapeutics Stock Down 2.7%

Shares of TRVI stock opened at $14.26 on Thursday. The company has a 50 day moving average price of $12.63 and a 200-day moving average price of $11.92. The firm has a market capitalization of $1.83 billion, a PE ratio of -44.56 and a beta of 1.07. Trevi Therapeutics has a 52 week low of $5.38 and a 52 week high of $16.12.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02).

Hedge Funds Weigh In On Trevi Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in Trevi Therapeutics by 4.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company's stock worth $195,000 after purchasing an additional 911 shares during the period. Hilton Head Capital Partners LLC raised its holdings in Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company's stock worth $51,000 after purchasing an additional 1,044 shares during the period. Ameritas Investment Partners Inc. raised its holdings in Trevi Therapeutics by 20.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company's stock worth $70,000 after purchasing an additional 1,300 shares during the period. Kennedy Capital Management LLC raised its holdings in Trevi Therapeutics by 2.4% during the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company's stock valued at $704,000 after acquiring an additional 1,336 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company's stock valued at $78,000 after acquiring an additional 1,523 shares during the period. 95.76% of the stock is owned by institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.